X0306 4 2020-05-06 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001789815 Tatsis Ourania C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Regulatory Officer Common Stock 2020-05-06 4 M 0 559 187.53 A 13297 D Common Stock 2020-05-06 4 M 0 407 155.57 A 13704 D Common Stock 2020-05-06 4 S 0 43 268.80 D 13661 D Common Stock 2020-05-06 4 S 0 136 270.19 D 13525 D Common Stock 2020-05-06 4 S 0 217 272.09 D 13308 D Common Stock 2020-05-06 4 S 0 210 273.15 D 13098 D Common Stock 2020-05-06 4 S 0 330 274.13 D 12768 D Common Stock 2020-05-06 4 S 0 30 275.30 D 12738 D Stock Option (Right to Buy) 187.53 2020-05-06 4 M 0 559 0.00 D 2029-02-05 Common Stock 559 6145 D Stock Option (Right to Buy) 155.57 2020-05-06 4 M 0 407 0.00 D 2028-02-05 Common Stock 407 2854 D Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $268.80 (range $268.65 to $269.12). Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $270.19 (range $269.71 to $270.61). Open market sales reported on this line occurred at a weighted average price of $272.09 (range $271.73 to $272.54). Open market sales reported on this line occurred at a weighted average price of $273.15 (range $272.73 to $273.50). Open market sales reported on this line occurred at a weighted average price of $274.13 (range $273.75 to $274.73). The option vests in 16 quarterly installments from 02/06/2019. The option vests in 16 quarterly installments from 02/06/2018. /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-08